XJSE
APN
Market cap3.87bUSD
Jun 19, Last price
15,425.00ZAR
1D
4.17%
1Q
17.38%
Jan 2017
-45.61%
Name
Aspen Pharmacare Holdings Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aspen Pharmacare Holdings Limited is a global pharmaceutical entity that develops, manufactures, and distributes a wide array of specialized and branded medicinal products. The company operates through two primary segments: Commercial Pharmaceuticals and Manufacturing. Its diverse product portfolio encompasses essential anesthetic agents, such as general anesthetics, muscle relaxants, and topical preparations. Aspen also provides a comprehensive suite of thrombosis treatments, including various injectable anticoagulants like low molecular weight heparins, Xa inhibitors, and other heparin derivatives. Beyond these, the firm markets numerous regional consumer, prescription, and over-the-counter brands, such as Circadin for sleep, Foxair for respiratory ailments, Maltofer as an iron supplement, Mybulen for pain management, and Zyloric for gout. Additionally, Aspen produces active pharmaceutical ingredients and finished dose form products for other companies. Established in 1850, the company's headquarters are located in Durban, South Africa.
Valuation
Title ZAR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||